A phase I trial assessing the safety and tolerability of the oral combination of panobinostat and ruxolitinib in patients with myelofibrosis
Latest Information Update: 29 Jul 2020
At a glance
- Drugs Panobinostat (Primary) ; Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis
- Focus Adverse reactions
Most Recent Events
- 29 Jul 2020 New trial record